Shares of Immunome Inc. (IMNM) soared 5.17% during Tuesday's intraday trading session, showcasing significant investor interest in the biotechnology company. The stock's upward movement comes amidst positive analyst sentiment, reinforcing market confidence in Immunome's potential.

The catalyst for this surge appears to be a recent reaffirmation of a Buy rating by TD Cowen analyst Tyler Van Buren. On November 7, Van Buren maintained a bullish stance on IMNM stock, signaling continued optimism about the company's prospects. This vote of confidence from a respected financial institution has evidently resonated with investors, driving up demand for Immunome shares.

Immunome Inc. is known for its work in the field of immunology and antibody-based therapeutics. While specific details about the company's recent advancements are limited in the provided information, the maintained Buy rating suggests that analysts see promise in Immunome's clinical progress and strategic direction. As always, investors are advised to conduct their own research and consider multiple factors before making investment decisions.